BULLSEYE: Lu-PSMA in Oligometastatic HSPC

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Bastiaan Privé, MD, Radboud University Medical Centre, and Scott Tagawa, MD, Weill Cornell Medicine, discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic hormone sensitive prostate cancer.

Following surgery and external beam radiotherapy, this option has the potential to become a third MDT option for oligometastatic prostate cancer patients to prolong an ADT-free interval.
Category
Oncology
Be the first to comment

Up Next